Garcia M J, Dominguez-Gil A, Tabernero J M, Sanchez Tomero J A
Eur J Clin Pharmacol. 1979 Sep;16(2):119-24. doi: 10.1007/BF00563118.
The pharmacokinetics of cefoxitin have been determined after a single i.v. injection of 15 mg/kg body weight in 10 patients with normal renal function and 20 patients with varying degrees of renal impairment. The kinetics of the antibiotic followed an open two-compartment model. In patients with normal renal function the following pharmacokinetic parameters were found: alpha = 8.66 h-1 beta = 1.21 h-1 K12 = 3.47 h-1 K21 = 3.17 h-1 K13 = 3.15 h-1 Vc = 4.24 l. Vp = 4.87 l. Vdss = 9.11 l. In the patients with renal impairment there was a significant decrease in alpha, beta, K12, K21 and K13, and an increase in the apparent volume of distribution. The degree of plasma protein binding in patients with normal renal function was 73.6% and this was diminished in patients with renal impairment. A linear relationship between K13 of cefoxitin and creatinine clearance was demonstrated. The dosage regimen for patients with renal impairment should be adjusted by modifying the dosage interval whilst maintaining the amount administered.
在10名肾功能正常的患者和20名不同程度肾功能损害的患者中,静脉注射15mg/kg体重的头孢西丁后,测定了其药代动力学。抗生素的动力学遵循开放二室模型。在肾功能正常的患者中,发现以下药代动力学参数:α = 8.66 h⁻¹,β = 1.21 h⁻¹,K12 = 3.47 h⁻¹,K21 = 3.17 h⁻¹,K13 = 3.15 h⁻¹,Vc = 4.24 l,Vp = 4.87 l,Vdss = 9.11 l。在肾功能损害的患者中,α、β、K12、K21和K13显著降低,表观分布容积增加。肾功能正常患者的血浆蛋白结合率为73.6%,肾功能损害患者的血浆蛋白结合率降低。头孢西丁的K13与肌酐清除率之间呈线性关系。肾功能损害患者的给药方案应通过调整给药间隔同时维持给药量来进行调整。